ANGO vs. IART, ATRC, ATEC, OFIX, SRDX, ARAY, RMTI, RSLS, ABT, and ISRG
Should you be buying AngioDynamics stock or one of its competitors? The main competitors of AngioDynamics include Integra LifeSciences (IART), AtriCure (ATRC), Alphatec (ATEC), Orthofix Medical (OFIX), Surmodics (SRDX), Accuray (ARAY), Rockwell Medical (RMTI), ReShape Lifesciences (RSLS), Abbott Laboratories (ABT), and Intuitive Surgical (ISRG). These companies are all part of the "health care equipment" industry.
AngioDynamics vs.
Integra LifeSciences (NASDAQ:IART) and AngioDynamics (NASDAQ:ANGO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their community ranking, valuation, dividends, institutional ownership, risk, media sentiment, profitability, analyst recommendations and earnings.
84.8% of Integra LifeSciences shares are owned by institutional investors. Comparatively, 89.4% of AngioDynamics shares are owned by institutional investors. 3.1% of Integra LifeSciences shares are owned by company insiders. Comparatively, 5.4% of AngioDynamics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Integra LifeSciences presently has a consensus price target of $23.00, suggesting a potential downside of 4.56%. AngioDynamics has a consensus price target of $13.00, suggesting a potential upside of 4.59%. Given AngioDynamics' stronger consensus rating and higher possible upside, analysts clearly believe AngioDynamics is more favorable than Integra LifeSciences.
Integra LifeSciences has higher revenue and earnings than AngioDynamics. Integra LifeSciences is trading at a lower price-to-earnings ratio than AngioDynamics, indicating that it is currently the more affordable of the two stocks.
Integra LifeSciences has a net margin of -0.42% compared to AngioDynamics' net margin of -79.38%. Integra LifeSciences' return on equity of 12.35% beat AngioDynamics' return on equity.
Integra LifeSciences received 68 more outperform votes than AngioDynamics when rated by MarketBeat users. However, 61.19% of users gave AngioDynamics an outperform vote while only 56.83% of users gave Integra LifeSciences an outperform vote.
Integra LifeSciences has a beta of 1.16, meaning that its share price is 16% more volatile than the S&P 500. Comparatively, AngioDynamics has a beta of 0.59, meaning that its share price is 41% less volatile than the S&P 500.
In the previous week, AngioDynamics had 7 more articles in the media than Integra LifeSciences. MarketBeat recorded 11 mentions for AngioDynamics and 4 mentions for Integra LifeSciences. AngioDynamics' average media sentiment score of 1.00 beat Integra LifeSciences' score of 0.49 indicating that AngioDynamics is being referred to more favorably in the news media.
Summary
AngioDynamics beats Integra LifeSciences on 9 of the 17 factors compared between the two stocks.
Get AngioDynamics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ANGO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AngioDynamics Competitors List
Related Companies and Tools
This page (NASDAQ:ANGO) was last updated on 1/21/2025 by MarketBeat.com Staff
